Zepbound vs Mounjaro: Same Drug, Different Purpose

If you've been researching GLP-1 medications for weight loss, you've likely encountered both Zepbound and Mounjaro and wondered what the difference is. The short answer: they're the same drug, made by the same company (Eli Lilly), with the same active ingredient (tirzepatide) at the same doses. The longer answer involves FDA approvals, insurance coverage, and some practical implications that matter for how you access the medication.

What's actually the same

• Active ingredient: Tirzepatide — identical in both
• Mechanism: Dual GLP-1 and GIP receptor agonist
• Doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
• Administration: Weekly subcutaneous injection, same pen format
• Titration schedule: Identical
• Side effect profile: Identical
• Manufacturer: Eli Lilly

What's different

FDA approval indication

Mounjaro was FDA-approved in May 2022 for the treatment of type 2 diabetes. Zepbound was FDA-approved in November 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

The same compound went through separate clinical trials for each indication (the SURPASS trials for diabetes, the SURMOUNT trials for obesity) and received separate approvals for each.

Insurance coverage

This is the most practically important difference. Insurance coverage for Mounjaro (diabetes indication) vs Zepbound (obesity indication) varies dramatically by plan:

• Many insurance plans that cover diabetes medications cover Mounjaro if you have a type 2 diabetes diagnosis
• Coverage for Zepbound (obesity) is less consistent — many plans explicitly exclude weight loss medications
• Some plans cover Zepbound for obesity with documented comorbidities
• Medicare Part D covers Zepbound for obesity starting in 2026 under certain conditions

In practice, some providers have prescribed Mounjaro off-label for weight loss in patients without diabetes when coverage was better. This is legal but varies by provider and insurer.

List price

Both have similar list prices (~$1,000+/month), but Eli Lilly offers separate savings programs. The Zepbound savings card has sometimes offered lower out-of-pocket costs for commercially insured patients. It's worth checking both programs if you're paying out of pocket.

Which should you ask for?

The decision is mostly driven by your insurance situation:

• If you have type 2 diabetes and your insurance covers Mounjaro — Mounjaro
• If you don't have diabetes and your insurance covers weight loss medications — Zepbound
• If you're paying out of pocket — compare the Lilly savings programs for both; Zepbound has sometimes been cheaper

Your provider will prescribe whichever is appropriate for your diagnosis. The clinical experience — the medication, the doses, the side effects, the results — will be identical either way.

Tracking either medication

Since Mounjaro and Zepbound are medically identical, everything about tracking applies equally to both: logging injection dates, doses, sites, and your weekly weight response. The patterns you'll see in your data — dose bumps, pre-injection slowdowns, energy changes at higher doses — are the same regardless of which brand name is on the pen.